GETI.B

212.4

+1.14%↑

BIOAB

319.8

-0.12%↓

EKTA.B

56.2

+1.35%↑

VITR

137

-0.72%↓

AMBEA

138.9

+1.31%↑

GETI.B

212.4

+1.14%↑

BIOAB

319.8

-0.12%↓

EKTA.B

56.2

+1.35%↑

VITR

137

-0.72%↓

AMBEA

138.9

+1.31%↑

GETI.B

212.4

+1.14%↑

BIOAB

319.8

-0.12%↓

EKTA.B

56.2

+1.35%↑

VITR

137

-0.72%↓

AMBEA

138.9

+1.31%↑

GETI.B

212.4

+1.14%↑

BIOAB

319.8

-0.12%↓

EKTA.B

56.2

+1.35%↑

VITR

137

-0.72%↓

AMBEA

138.9

+1.31%↑

GETI.B

212.4

+1.14%↑

BIOAB

319.8

-0.12%↓

EKTA.B

56.2

+1.35%↑

VITR

137

-0.72%↓

AMBEA

138.9

+1.31%↑

Home・Aandelen Lijst・Camurus AB

Camurus AB

Gesloten

610.5 0.25

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

602

Max

612.5

Belangrijke statistieken
By Trading Economics
Inkomsten	-99M 193M
Verkoop	-108M 567M
K/W Sectorgemiddelde	45.821 77.671
EPS	3.19
Winstmarge	33.972
Werknemers	280
EBITDA	-62M 253M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-492M 36B
Vorige openingsprijs	610.25
Vorige sluitingsprijs	610.5

Camurus AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 dec 2025, 22:53 UTC

Acquisities, Fusies, Overnames

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dec 2025, 00:04 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dec 2025, 23:46 UTC

Marktinformatie

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dec 2025, 22:38 UTC

Acquisities, Fusies, Overnames

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dec 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dec 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dec 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Fortescue to Acquire Remaining 64% of Alta Copper

14 dec 2025, 17:00 UTC

Winsten

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dec 2025, 16:48 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 08:00 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 07:00 UTC

Acquisities, Fusies, Overnames

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dec 2025, 00:24 UTC

Acquisities, Fusies, Overnames

Want a Piece Of SpaceX? -- Barrons.com

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer Vergelijking

Prijswijziging

Camurus AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.